Pharma Outlook for 2017
Tuesday, February 7, 2017 – 1:00 PM ET


Pharma companies in the months ahead are poised to continue see many opportunities as they navigate through wildcard issues including the concern around drug pricing as well as regulatory scrutiny on compliance and reimbursement challenges. At the same time, many drugmakers will likely remain under pressure to refill their portfolios as patents for blockbuster drugs approach the end of their lifespan, thus facing competition from new entrants.

In matters of regulation, the potential for tax reform and the increasing odds that drugmakers are permitted to repatriate huge sums of trapped cash overseas could prove to be a major capital driver for the industry. In other words, Big Pharma may have even more fuel to go after smaller players, unless they simply opt to reward shareholders with higher dividends and stock buybacks. One way or another, demand for healthcare and new, innovative therapies isn’t going anywhere.

With a panel of experts, The Deal’s video roundtable on February 7th will help you narrow down where to look for opportunities in pharma and the hot button issues investors ought to keep tabs on in 2017.



Daniel Perez
Director of Business Strategy, Venue Virtual Data Room
Donnelley Financial Solutions

Daniel Perez is Director of Business Strategy for Donnelley Financial Solutions' Venue virtual data room platform, with responsibility for the strategic marketing and branding direction for Venue globally. Daniel has been with Donnelley Financial Solutions 4 years, and prior to joining DFS, he worked at both NBC Universal and BBC America in the digital media and marketing divisions in New York. Prior to moving to New York, Daniel worked both as in-house and agency marketing roles in Las Vegas, as well as executive producing a television series for the City of Las Vegas. Mr. Perez holds a Bachelors Degree in Business and Psychology from Pepperdine University and a MBA from the Gabelli School of Business at Fordham University.